Astellas makes a big to acquire CV Therapeutics. Japan’s Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday’s close.
Abilify as an add-on therapy for depression – not everyone is convinced.
Watson‘s topical Overactive Bladder gel (Gelnique) gets FDA approval.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.